II. Indications
- Cutaneous T Cell Lymphoma (Mycosis Fungoides, Sezary Syndrome)
III. Mechanism
- CCR4 (Chemokine receptor 4)
- CCR4 is a cell surface receptor that binds Cytokines (CCL2, CCL4, CCL5, CCL17 and CCL22)
- CCR4 Receptors are most commonly expressed on T-Lymphocytes, Mast Cells, Dendritic Cells and Natural Killer Cells
- CCR4 binding by Cytokine triggers chemotaxis of inflammatory cells (e.g. Natural Killer Cells)
- CCR4 Monoclonal Antibody (e.g. Mogamulizumab)
- Humanized Monoclonal Antibody selectively binds CCR4 and blocks chemotaxis, T-Cell proliferation and Angiogenesis
IV. Medications
- Mogamulizumab-kpkc (Poteligeo) solution for injection
V. Dosing
- See other references for disease specific dosing protocols
VI. Adverse Effects
- Infusion Reaction
- Dermatitis
- Hold for moderate to severe dermatitis
-
Graft Versus Host Disease
- Status-post transplant patients
- Other common adverse effects
- Diarrhea
- Myalgias
VII. Safety
- Avoid in Lactation
- Avoid in pregnancy (all trimesters, unknown safety)
- Use reliable Contraception
VIII. Resources
- Mogamulizumab (DailyMed)